Wellgistics Health Announces Pricing of $5 Million Public Offering

Rhea-AI Summary

Wellgistics Health (NASDAQ:WGRX), a pharmaceutical distribution and AI-powered hub fulfillment company, has announced the pricing of a $5 million public offering. The offering consists of 7,142,862 shares of common stock and warrants at a combined price of $0.70 per share and associated warrant.

The warrants will have an exercise price of $0.70 per share, be exercisable upon issuance, and expire in five years. The offering, expected to close around September 29, 2025, is being managed by H.C. Wainwright & Co. as the exclusive placement agent. The company plans to use the proceeds for working capital, operating expenses, R&D, and potential acquisitions.

Positive

• Secured $5 million in additional funding for working capital and growth initiatives
• Warrants provide potential for additional future funding at $0.70 per share
• Successful registration and SEC approval of Form S-1 offering

Negative

• Significant shareholder dilution through issuance of 7.14M new shares
• Offering price of $0.70 suggests challenging market conditions or company valuation
• Additional dilution possible if warrants are exercised

Insights

Financial Analyst

Wellgistics Health's $5M offering at $0.70/share signals significant dilution, raising liquidity concerns despite providing short-term capital.

Wellgistics Health's $5 million public offering reveals concerning details about the company's financial position. The offering price of $0.70 per share likely represents a significant discount to recent trading prices, which is typically a negative signal. The company is issuing 7,142,862 new shares plus an equal number of warrants, representing substantial dilution for existing shareholders.

The warrant structure is particularly noteworthy - they're exercisable immediately at the same $0.70 price as the offering with a five-year term. This suggests the company needed attractive terms to secure investor interest. If these warrants are eventually exercised, they would bring in additional capital but double the dilution impact.

The stated use of proceeds for "working capital and general corporate purposes" lacks specificity and could indicate immediate liquidity needs rather than strategic growth initiatives. The inclusion of "pending and future acquisitions" as a potential use seems aspirational given the modest size of the raise.

The exclusive placement through H.C. Wainwright rather than a broader underwriting syndicate may reflect limited institutional interest. For a NASDAQ-listed company in the pharmaceutical space, a $5 million raise is relatively small, suggesting this may be a stopgap measure rather than transformative capital. Investors should carefully monitor the company's cash burn rate and operational efficiency following this offering.

TAMPA, FL / ACCESS Newswire / September 25, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced the pricing of a public offering of 7,142,862 shares of common stock, together with warrants to purchase up to 7,142,862 shares of common stock at a combined public offering price of $0.70 per share and associated warrant. The warrants will have an exercise price of $0.70 per share, will be exercisable upon issuance and will expire five years thereafter. The closing of the offering is expected to occur on or about September 29, 2025, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The gross proceeds to the Company from the offering are expected to be approximately $5 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes, which may include operating expenses, research and development, and pending and future acquisitions.

A registration statement on Form S-1 (File No. 333-288932) relating to the offering was declared effective by the Securities and Exchange Commission (the "SEC") on September 25, 2025. The offering is being made only by means of a prospectus forming part of the effective registration statement relating to the offering. A preliminary prospectus relating to the offering has been filed with the SEC. Electronic copies of the final prospectus, when available, may be obtained on the SEC's website at http://www.sec.gov and may also be obtained, when available, by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Wellgistics Health

Wellgistics Health, Inc. (NASDAQ:WGRX) delivers medications from manufacturer to patient-faster, smarter, and more affordably. Its integrated platform connects more than 6,500 independent pharmacies and 200+ U.S. manufacturers, offering wholesale distribution, digital prescription routing, and AI-driven hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment. As a PBM-agnostic alternative, Wellgistics Health provides compliant, end-to-end solutions designed to restore access, transparency, and trust in U.S. healthcare.

Forward-Looking Statements

This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate," or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, statements regarding Wellgistics Health's strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially from Wellgistics Health's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, market conditions, the completion of the offering, the satisfaction of customary closing conditions related to the offering, the intended use of net proceeds from the offering and other risks detailed in our reports and statements filed with the SEC. Investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in Wellgistics Health's filings with the SEC, available at www.sec.gov.

Media & Investor Contact

Media:
media@wellgisticshealth.com

Investor Relations:
IR@wellgisticshealth.com

Investor Relations Contact:
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, NY 10036
Office: (646) 893-5835
Email: info@skylineccg.com

SOURCE: Wellgistics Health, Inc.

View the original press release on ACCESS Newswire

FAQ

What is the size and price of Wellgistics Health (WGRX) public offering in September 2025?

Wellgistics Health priced a $5 million public offering consisting of 7,142,862 shares and warrants at $0.70 per share and associated warrant.

How will Wellgistics Health (WGRX) use the proceeds from the $5M offering?

The company will use the proceeds for working capital, general corporate purposes, operating expenses, R&D, and potential acquisitions.

What are the terms of the WGRX warrants issued in the September 2025 offering?

The warrants have an exercise price of $0.70 per share, are exercisable immediately upon issuance, and will expire in five years.

When will Wellgistics Health's (WGRX) public offering close?

The offering is expected to close on or about September 29, 2025, subject to customary closing conditions.

Who is the placement agent for Wellgistics Health's (WGRX) public offering?

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.